Palatin Technologies (PTN) said Friday that topline results from its phase 2 study of PL8177 in patients with active ulcerative colitis showed clinical remission in 33% of treated patients after eight weeks of treatment, while none in the placebo group achieved remission.
Nine of the 12 patients received PL8177, and 78% of the treated group showed a clinical response, according to the company.
CEO Carl Spana said the strong data, along with prior findings, supports ongoing licensing discussions with multiple pharmaceutical companies.
Shares of Palatin were down 7.6% in recent trading.
Price: 0.65, Change: -0.05, Percent Change: -7.57
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。